BioAtla (BCAB) Competitors $1.18 -0.13 (-9.92%) (As of 12/18/2024 05:44 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCAB vs. ATYR, MRSN, CMRX, HRTX, FULC, ACB, LXEO, DMAC, FATE, and ZNTLShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Atyr PHARMA (ATYR), Mersana Therapeutics (MRSN), Chimerix (CMRX), Heron Therapeutics (HRTX), Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), Fate Therapeutics (FATE), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Atyr PHARMA Mersana Therapeutics Chimerix Heron Therapeutics Fulcrum Therapeutics Aurora Cannabis Lexeo Therapeutics DiaMedica Therapeutics Fate Therapeutics Zentalis Pharmaceuticals BioAtla (NASDAQ:BCAB) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Does the media favor BCAB or ATYR? In the previous week, BioAtla and BioAtla both had 2 articles in the media. Atyr PHARMA's average media sentiment score of 0.51 beat BioAtla's score of 0.25 indicating that Atyr PHARMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atyr PHARMA 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, BCAB or ATYR? Atyr PHARMA has lower revenue, but higher earnings than BioAtla. Atyr PHARMA is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M5.19-$123.46M-$1.70-0.69Atyr PHARMA$235K1,125.18-$50.39M-$0.94-3.35 Is BCAB or ATYR more profitable? Atyr PHARMA's return on equity of -79.44% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -187.30% -96.33% Atyr PHARMA N/A -79.44%-59.16% Which has more volatility & risk, BCAB or ATYR? BioAtla has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Do insiders & institutionals believe in BCAB or ATYR? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer BCAB or ATYR? BioAtla received 16 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 67.57% of users gave BioAtla an outperform vote. CompanyUnderperformOutperformBioAtlaOutperform Votes2567.57% Underperform Votes1232.43% Atyr PHARMAOutperform Votes9100.00% Underperform VotesNo Votes Do analysts prefer BCAB or ATYR? BioAtla currently has a consensus price target of $6.00, indicating a potential upside of 408.47%. Atyr PHARMA has a consensus price target of $19.25, indicating a potential upside of 511.11%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, analysts clearly believe Atyr PHARMA is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtyr PHARMA beats BioAtla on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.05M$2.88B$5.03B$8.97BDividend YieldN/A1.85%4.80%4.06%P/E Ratio-0.6945.91134.6816.91Price / Sales5.19400.741,134.38116.20Price / CashN/A182.1340.5137.94Price / Book0.803.744.744.71Net Income-$123.46M-$42.03M$118.37M$225.20M7 Day Performance-17.48%-5.25%11.28%-2.58%1 Month Performance-21.33%1.93%9.41%3.57%1 Year Performance-40.85%13.48%29.70%16.54% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.7029 of 5 stars$1.18-9.9%$6.00+408.5%-40.6%$57.05M$11M-0.6960Gap UpATYRAtyr PHARMA2.7127 of 5 stars$3.11+1.6%$19.25+519.0%N/A$261.06M$235,000.00-3.2656MRSNMersana Therapeutics4.3605 of 5 stars$2.10-2.3%$6.00+185.7%-14.2%$259.41M$36.85M-3.52150Positive NewsCMRXChimerix4.3295 of 5 stars$2.86-3.1%$8.50+197.2%+185.2%$257.23M$320,000.00-3.1472HRTXHeron Therapeutics4.1292 of 5 stars$1.68+4.7%$5.67+238.3%-9.8%$254.76M$137.74M-8.89300Analyst DowngradeFULCFulcrum Therapeutics2.2006 of 5 stars$4.42+11.6%$9.33+111.2%-23.1%$238.41M$80.87M-13.68100Positive NewsACBAurora Cannabis0.2069 of 5 stars$4.28-0.7%N/A-9.0%$234.72M$200.35M-5.671,073LXEOLexeo Therapeutics2.6994 of 5 stars$7.01+1.9%$23.80+239.5%-53.2%$231.79M$650,000.00-2.1858DMACDiaMedica Therapeutics2.9194 of 5 stars$5.40+0.4%$7.00+29.6%+75.3%$230.90MN/A-9.6120News CoveragePositive NewsFATEFate Therapeutics3.535 of 5 stars$2.02+10.4%$6.75+234.1%-46.5%$230.12M$13.45M-1.22550ZNTLZentalis Pharmaceuticals2.7093 of 5 stars$3.22+4.2%$10.00+210.6%-79.0%$229.46MN/A-1.24160 Related Companies and Tools Related Companies ATYR Alternatives MRSN Alternatives CMRX Alternatives HRTX Alternatives FULC Alternatives ACB Alternatives LXEO Alternatives DMAC Alternatives FATE Alternatives ZNTL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCAB) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAB Stock Alerts